Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Etanercept curbs psoriasis in children

Etanercept can substantially reduce the severity of psoriasis in children and adolescents, a US trial reports.

In the 48-week study, 211 patients with psoriasis, aged from four to 17 years, were initially randomly assigned to 12 once-weekly injections of either 0.8mg etanercept or placebo, followed by 24 weeks of open-label etanercept.

After the initial 12 weeks' treatment, 53% of patients on etanercept were assessed as being clear or almost clear of psoriasis, compared with 13% on placebo.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say